Bruker Corporation (NASDAQ:BRKR) Receives Average Recommendation of “Hold” from Analysts

Shares of Bruker Corporation (NASDAQ:BRKR) have been assigned a consensus recommendation of “Hold” from the seventeen analysts that are currently covering the firm, Marketbeat.com reports. Two investment analysts have rated the stock with a sell recommendation, six have assigned a hold recommendation, eight have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $51.50.

A number of equities analysts have recently commented on BRKR shares. UBS Group lifted their price target on shares of Bruker from $40.00 to $43.00 and gave the company a “neutral” rating in a research report on Tuesday, November 4th. Guggenheim lifted their target price on shares of Bruker from $45.00 to $53.00 and gave the stock a “buy” rating in a report on Monday. Rothschild & Co Redburn assumed coverage on Bruker in a research report on Thursday, November 20th. They issued a “buy” rating and a $60.00 price target on the stock. Wells Fargo & Company boosted their price objective on Bruker from $48.00 to $55.00 and gave the stock an “overweight” rating in a research report on Monday, December 15th. Finally, JPMorgan Chase & Co. increased their target price on Bruker from $50.00 to $55.00 and gave the company an “overweight” rating in a research note on Monday, December 15th.

Insider Transactions at Bruker

In related news, Director John A. Ornell sold 6,233 shares of the stock in a transaction dated Thursday, November 6th. The shares were sold at an average price of $39.00, for a total value of $243,087.00. Following the completion of the transaction, the director owned 35,212 shares of the company’s stock, valued at $1,373,268. This represents a 15.04% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 27.30% of the stock is owned by company insiders.

Institutional Trading of Bruker

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Nisa Investment Advisors LLC lifted its stake in shares of Bruker by 377.5% in the 2nd quarter. Nisa Investment Advisors LLC now owns 616 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 487 shares during the period. Allworth Financial LP increased its stake in Bruker by 40.6% during the 3rd quarter. Allworth Financial LP now owns 890 shares of the medical research company’s stock worth $29,000 after purchasing an additional 257 shares in the last quarter. Huntington National Bank raised its holdings in shares of Bruker by 750.0% during the second quarter. Huntington National Bank now owns 731 shares of the medical research company’s stock worth $30,000 after acquiring an additional 645 shares during the period. Spire Wealth Management acquired a new stake in shares of Bruker in the 2nd quarter valued at about $32,000. Finally, Parallel Advisors LLC lifted its stake in Bruker by 63.0% in the 2nd quarter. Parallel Advisors LLC now owns 898 shares of the medical research company’s stock valued at $37,000 after acquiring an additional 347 shares in the last quarter. 79.52% of the stock is owned by institutional investors.

Bruker Price Performance

NASDAQ BRKR opened at $52.67 on Wednesday. The firm has a market cap of $8.00 billion, a P/E ratio of -329.19, a price-to-earnings-growth ratio of 6.64 and a beta of 1.17. The stock’s 50-day moving average is $45.20 and its two-hundred day moving average is $39.45. Bruker has a fifty-two week low of $28.53 and a fifty-two week high of $64.64. The company has a debt-to-equity ratio of 0.81, a current ratio of 1.85 and a quick ratio of 0.91.

Bruker (NASDAQ:BRKR) last issued its quarterly earnings data on Monday, November 3rd. The medical research company reported $0.45 earnings per share for the quarter, beating analysts’ consensus estimates of $0.33 by $0.12. Bruker had a positive return on equity of 15.45% and a negative net margin of 0.61%.The business had revenue of $860.50 million for the quarter, compared to the consensus estimate of $847.40 million. During the same period last year, the business earned $0.60 EPS. The firm’s revenue was down .5% compared to the same quarter last year. Bruker has set its FY 2025 guidance at 1.850-1.90 EPS. On average, analysts anticipate that Bruker will post 2.69 earnings per share for the current fiscal year.

Bruker Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, January 2nd. Stockholders of record on Monday, December 8th were paid a $0.05 dividend. The ex-dividend date was Monday, December 8th. This represents a $0.20 annualized dividend and a dividend yield of 0.4%. Bruker’s dividend payout ratio (DPR) is presently -125.00%.

About Bruker

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.